# Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/rare-diseases-natural-history-studies-for-drug-development-draft-guidance-for-industry/a0f2f4af-4b97-4e7b-8e82-b4911a5d32e4

> FDA guidance document: Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry. Issue date: March 25, 2019. Get complete insights and analysis.

---

## Details

- Title: Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: other
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-03-25
- Comment Close Date: 2019-05-24
- Last Changed: 2020-04-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-0481">FDA-2019-D-0481</a>

## Related Documents

- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/rare-diseases-early-drug-development-and-the-role-of-pre-ind-meetings-draft-guidance-for-industry/3c7d812a-8f9d-42ac-b54e-ad63ed389dab)
- [Early Alzheimer’s Disease: Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/early-alzheimers-disease-developing-drugs-for-treatment/ef0ff9a7-7208-4951-acbb-acb9937f83e7)